| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99284 |
Emergency department visit for the evaluation and management, high severity |
8,924 |
7,602 |
$1.15M |
| G0378 |
Hospital observation service, per hour |
1,407 |
1,216 |
$672K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
2,677 |
2,425 |
$426K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
1,276 |
1,165 |
$88K |
| 41899 |
Unlisted procedure, dentoalveolar structures |
55 |
54 |
$75K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
4,304 |
3,395 |
$72K |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
152 |
95 |
$27K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
532 |
396 |
$24K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
2,197 |
552 |
$13K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
11,409 |
8,579 |
$7K |
| 71046 |
Radiologic examination, chest; 2 views |
1,098 |
1,038 |
$5K |
| 80053 |
Comprehensive metabolic panel |
6,470 |
5,345 |
$4K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
1,222 |
1,085 |
$3K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
3,452 |
3,054 |
$2K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
5,244 |
3,966 |
$2K |
| 84484 |
|
2,879 |
2,367 |
$2K |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
2,303 |
1,787 |
$1K |
| 70450 |
Computed tomography, head or brain; without contrast material |
1,411 |
1,332 |
$1K |
| 97162 |
|
27 |
26 |
$1K |
| 81001 |
|
3,812 |
3,387 |
$1K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
171 |
160 |
$911.33 |
| 87631 |
|
61 |
60 |
$711.74 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
101 |
96 |
$573.14 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
92 |
83 |
$470.14 |
| 83690 |
|
1,876 |
1,555 |
$442.20 |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
159 |
141 |
$409.87 |
| 71045 |
Radiologic examination, chest; single view |
1,216 |
1,119 |
$397.14 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
398 |
360 |
$330.57 |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
642 |
169 |
$303.46 |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
251 |
234 |
$197.63 |
| 84703 |
|
230 |
209 |
$188.40 |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
321 |
284 |
$144.32 |
| J2274 |
Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg |
1,128 |
704 |
$137.30 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
1,296 |
964 |
$135.80 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,291 |
1,064 |
$135.08 |
| 82948 |
|
3,537 |
2,146 |
$117.53 |
| 82248 |
|
1,546 |
1,377 |
$86.46 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
2,870 |
2,155 |
$60.46 |
| 80076 |
|
128 |
119 |
$45.56 |
| 85610 |
|
126 |
91 |
$39.79 |
| 36415 |
Collection of venous blood by venipuncture |
423 |
333 |
$35.14 |
| J3490 |
Unclassified drugs |
790 |
649 |
$23.00 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
1,920 |
1,469 |
$19.05 |
| J2704 |
Injection, propofol, 10 mg |
1,523 |
1,323 |
$14.04 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
932 |
767 |
$12.82 |
| 87077 |
|
12 |
12 |
$12.31 |
| 84443 |
Thyroid stimulating hormone (TSH) |
120 |
106 |
$10.81 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
1,500 |
1,347 |
$7.59 |
| 85014 |
|
20 |
12 |
$4.81 |
| J1644 |
Injection, heparin sodium, per 1000 units |
813 |
406 |
$3.52 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
1,747 |
1,374 |
$3.49 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
188 |
127 |
$3.43 |
| 82077 |
|
350 |
313 |
$0.00 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
309 |
260 |
$0.00 |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
148 |
140 |
$0.00 |
| 85027 |
|
45 |
36 |
$0.00 |
| 83880 |
|
115 |
107 |
$0.00 |
| 86901 |
|
27 |
24 |
$0.00 |
| 83605 |
|
105 |
89 |
$0.00 |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
82 |
78 |
$0.00 |
| C1769 |
Guide wire |
30 |
24 |
$0.00 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
17 |
13 |
$0.00 |
| 86850 |
|
27 |
24 |
$0.00 |
| 85379 |
|
15 |
13 |
$0.00 |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
143 |
132 |
$0.00 |
| G8978 |
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals |
122 |
114 |
$0.00 |
| 80179 |
|
226 |
206 |
$0.00 |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
141 |
129 |
$0.00 |
| 86900 |
|
27 |
24 |
$0.00 |
| 80143 |
|
226 |
206 |
$0.00 |
| 97164 |
|
12 |
12 |
$0.00 |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
168 |
79 |
$0.00 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
136 |
84 |
$0.00 |
| 81025 |
|
12 |
12 |
$0.00 |
| 71250 |
|
13 |
12 |
$0.00 |